TIGAR coordinates polyol and glutamine metabolism to regulate CD4+ T cells
This study reveals that the metabolic enzyme TIGAR regulates CD4+ T-cell differentiation and intestinal inflammation by coordinating glutamine and polyol metabolism, specifically through the suppression of aldose reductase, thereby identifying the polyol pathway as a novel therapeutic target for immune-mediated diseases.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The human immune system relies on a specialized squad of white blood cells known as CD4+ T cells to defend the body against infection. These cells act as master coordinators, deciding whether to launch an aggressive attack against a specific invader or to stand down and prevent the body from attacking itself. To make these life-or-death decisions, the cells do not just listen to chemical signals; they also rewire their internal energy factories. Just as a car engine requires different fuel mixes for racing versus idling, these immune cells shift their metabolism—how they burn sugar and fat—to match their mission. For decades, scientists believed that one specific enzyme, called TIGAR, acted primarily as a switch for this sugar-burning process, directing energy flow in a predictable way. However, the precise role this enzyme plays in the complex, untransformed immune cells of a living body has remained a mystery, leaving a gap in our understanding of how metabolism dictates the behavior of the immune system.
A team of researchers has now uncovered that TIGAR performs a far more surprising and critical job in CD4+ T cells than previously imagined. By studying mice engineered to lack this specific enzyme, the scientists discovered that TIGAR does not primarily control the burning of sugar, as once thought. Instead, it acts as a master regulator that balances two distinct metabolic pathways: one involving the breakdown of an amino acid called glutamine, and another involving a sugar-alcohol pathway known as the polyol pathway. When TIGAR is missing, the cells lose their ability to process glutamine efficiently. In response, the cells ramp up the production of an enzyme called aldose reductase, which converts glucose into a substance called sorbitol. This shift in chemistry forces the immune cell to change its identity, pushing it to become an inflammatory fighter rather than a peacekeeper.
The researchers found that without TIGAR, CD4+ T cells become hyper-active and prone to causing inflammation. In laboratory tests, cells lacking this enzyme produced significantly higher levels of interferon-gamma, a chemical signal that drives inflammation, while failing to generate the regulatory cells needed to calm the immune response. This behavior was not due to a failure in sugar metabolism, as the cells burned glucose at the same rate whether TIGAR was present or absent. Instead, the absence of TIGAR triggered a chain reaction where the buildup of sorbitol altered the cell's internal environment. This change encouraged the cells to move faster and scan their surroundings more aggressively, a behavior that mirrors the way cancer cells spread, but in this case, it drove the immune cells to cause tissue damage.
To see how this played out in a living organism, the team infected mice with a bacterium that causes gut inflammation. Mice with normal TIGAR levels managed the infection with a balanced immune response. However, mice lacking TIGAR in their T cells developed a much more severe inflammatory reaction. Their immune cells flooded the gut with inflammatory signals, leading to worse tissue damage and a higher risk of colitis. The study also looked at human data, using genetic information to trace the link between the enzyme that produces sorbitol and inflammatory bowel disease. The analysis suggested that in humans, higher levels of this enzyme are a direct cause of increased risk for conditions like Crohn's disease and ulcerative colitis. This finding connects the metabolic behavior of a single enzyme to the development of chronic human disease.
The study further revealed that the enzyme aldose reductase, which spikes when TIGAR is missing, is the key driver of this inflammatory shift. When the researchers used a drug to block this enzyme in normal cells, the cells stopped behaving like aggressive fighters and returned to a calmer state. Conversely, adding extra sorbitol to normal cells made them act like the aggressive, TIGAR-deficient cells. This confirmed that the polyol pathway is not just a side effect of metabolism but a central control mechanism for immune cell fate. The researchers also observed that the cells lacking TIGAR relied more heavily on burning fatty acids to fuel their mitochondria, the power plants of the cell, which allowed them to maintain high energy levels despite the metabolic imbalance.
These findings rewrite the understanding of how immune cells decide their fate. Rather than simply burning sugar, the cell's decision to become an inflammatory attacker or a regulatory peacekeeper is governed by a delicate balance between how it handles amino acids and sugar alcohols. The enzyme TIGAR serves as the guardian of this balance, ensuring that the cell does not overproduce sorbitol and spiral into a state of chronic inflammation. By identifying this metabolic switch, the research points to a new potential target for treating autoimmune diseases. If doctors can learn to modulate this specific pathway, they might be able to calm an overactive immune system without shutting it down completely, offering a new way to manage conditions where the body's own defenses turn against it.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.